For the first time in ten years, the combination of OS tecentriq in patients with liver cancer is superior to the first-line standard therapy

Recently, Roche announced that the combination therapy of atezolizumab (atezolizumab) and Avastin (bevacizumab) for PD-L1 antibody has achieved positive results in the three-stage test imbrave150 for patients with unresectable HCC who have not received systemic treatment before Data showed that the tecentriq / Avastin combination reduced the risk of death by 42% and the risk of disease progression or death by 41% compared with sorafenib This immunocombination therapy is the first clinical study in 10 years to prove that it is superior to the existing standard therapy sorafenib More than 750000 people are diagnosed with HCC every year, most of them in Asia and almost half of them in China In other areas, the incidence rate of liver cancer in Europe and the United States has been increasing Since 1980, the number of liver cancer cases in the United States has increased by more than two times Tecentriq, a PD-L1 inhibitor, has been approved in the United States, the European Union and other countries It can be used alone or in combination with targeted therapy or chemotherapy It can be used in various forms of non-small cell and small cell lung cancer, some types of metastatic urothelial cancer, and PD-L1 positive metastatic triple negative breast cancer Avastin is an antibody against vascular endothelial growth factor (VEGF), which interferes with the blood supply of tumor by directly combining with VEGF and inhibits the growth and spread of tumor The combination of tecentriq and Avastin may enhance the immune system's potential to deal with a wide range of cancers In July 2018, the U.S FDA awarded tecentriq / Avastin combination therapy breakthrough therapy certification, first-line treatment for advanced or metastatic HCC "For the first time in a decade, we've seen a treatment that improves the overall survival of patients with unresectable HCC compared to current standard therapies," said Dr Levi Garraway, Roche's chief medical officer and head of global product development Tecentriq in combination with Avastin may change the treatment of liver cancer We are working closely with the global health sector to bring this treatment to patients as soon as possible " In recent years, the combination therapy composed of inhibitors targeting PD-1 / PD-L1 pathway and VEGF signaling pathway has been approved by FDA four times Among them, the combination of keytruda / inlyta of MSD and bavencio / inlyta of Merck KGaA / Pfizer were approved for the first-line treatment of renal cell carcinoma The keytruda / lenvima combination of mesardon / Eisai was approved for the treatment of specific endometrial cancer patients Roche's tecentriq / Avastin / chemotherapy triple therapy was also approved for the treatment of non-small cell lung cancer This trial of tecentriq / Avastin combination therapy in the first-line treatment of liver cancer again achieved good results, showing the good prospect of this combination strategy At present, there are several combinations of immunocheckpoint inhibitors and anti angiogenic drugs that have been tested in clinical trials We hope that this combination strategy can benefit more patients.